Fig. 6: Targeting ribosome in the TME promotes ICB efficacy in the CT26 murine model.
From: Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy
a Heatmaps showing tissue prevalence of Lag3+ and Lag3- T/CD8+ T cells estimated by Ro/e score grouped by ctrl and CX-5461 treatment. b Bar plots showing proportion of Lag3+ CD8+ T cells estimated by flow cytometry assays grouped by ctrl and CX-5461 treatment. c Schematic showing therapy experiments of combined impact of CX-5461 and anti-Lag3 therapy. d Image of tumors at the end point. Scale bar = 1 cm. e Tumor weight at the end point. Data are shown as means ± SEM. f Tumor size over time during therapy. Data are shown as means ± SEM. g UMAP plots showing cellular ribosome biogenesis from each treatment group. h Boxplots showing cellular ribosome biogenesis from each treatment group. i UMAP plots showing cell types across treatment groups. j Heatmap showing tissue prevalence of each CD45+ cell type estimated by Ro/e score across treatment groups. k Heatmap showing expressions of activation and cytotoxic granules in CD8+ T cells across treatment groups. l Heatmap showing expressions of antigen processing and presentation genes in macrophage across treatment groups. m Heatmap showing expressions of INF/Inflam/LA/Reg-TAMs markers in macrophage across treatment groups.
